BriaCell Therapeutics Corp. (@BriaCell) / X

BriaCell Therapeutics Corp.

1,258 posts

BriaCell Therapeutics Corp.

@BriaCell

An immuno-oncology company developing targeted and effective immunotherapies for advanced breast cancer and other cancers. (Nasdaq: $BCTX, $BCTXL) (TSX: BCT)

Philadelphia, PA

Joined November 2014

BriaCell Therapeutics Corp.
@BriaCell
Oct 3, 2023
BriaCell's registration-enabling pivotal Phase 3 study of its lead clinical candidate, Bria-IMT™, in combination with an immune check point inhibitor, is approved by the IRB & will soon enroll patients with advanced metastatic #breastcancer. bit.ly/3thhD5I $BCTX $BCTXW
00:00
1.3M
BriaCell Therapeutics Corp.
@BriaCell
Mar 9, 2022
How Bria-IMT™ and Bria-OTS™ Destroy Cancer Cells (Video) youtube.com/watch?v=ZzsMVM…
BriaCell Therapeutics Corp.
@BriaCell
Nov 30, 2022
BriaCell has entered into a research collaboration and license agreement with @ImmunoPrecise's subsidiary @BioStrandBV to discover and develop anti-cancer antibodies. Find details: bit.ly/3OLVhQD $BCTX $BCTXW $IPA
BriaCell Therapeutics Corp.
@BriaCell
Sep 6, 2022
BriaCell's lead drug candidate, Bria-IMT™ (awarded Fast Track designation by the FDA), is a targeted #immunotherapy in phase I/IIa clinical testing for the treatment of advanced #breastcancer. Learn more: bit.ly/3q4udjN $BCTX $BCTXW
BriaCell Therapeutics Corp.
@BriaCell
Nov 10, 2022
Dr. William V. Williams, BriaCell’s President & CEO, comments on positive #breastcancer efficacy data with Bria-IMT™ #immunotherapy presented at the Company's poster session at the @sitcancer 37th Annual Meeting. Read more: bit.ly/3tp55G5 $BCTX $BCTXW
BriaCell Therapeutics Corp.
@BriaCell
Jan 18, 2023
BriaCell announced it has received agreement & positive feedback from its End of Phase II meeting with the FDA for BriaCell’s lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor, in advanced metastatic #breastcancer. bit.ly/3WisjKk $BCTX $BCTXW
17K
BriaCell Therapeutics Corp.
@BriaCell
Apr 13, 2022
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
globenewswire.com
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast...
BriaCell Therapeutics Corp.
@BriaCell
Apr 21, 2022
BriaCell; FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy Received buff.ly/3vTiNSP #breastcancer #breastcancertreatments #cancertreatments #cancer #research
BriaCell Therapeutics Corp.
@BriaCell
Jan 24, 2023
BriaCell today issues a letter to shareholders from Dr. William V. Williams, BriaCell's President and CEO. Read more: bit.ly/401VUL9 $BCTX $BCTXW
15K
BriaCell Therapeutics Corp.
@BriaCell
Jun 27, 2023
BriaCell announced that it has received approval from @US_FDA on its pivotal registrational study design for Bria-IMT™ in combination with a checkpoint inhibitor in advanced metastatic #breastcancer. For additional details: bit.ly/3pils9l $BCTX $BCTXW
4.3K
BriaCell Therapeutics Corp.
@BriaCell
Jul 28, 2021
Exciting news in breast cancer research. BriaCell is exploiting this biomarker in novel ways to personalize immunotherapy.
curetoday.com
Researchers Identify Biomarker to Predict Immunotherapy Response in Patients With Breast Cancer |...
The Major Histocompatibility Complex Class II protein has potential to predict immunotherapy benefit in two types of breast cancer.
BriaCell Therapeutics Corp.
@BriaCell
Jan 11, 2024
32 out of 42 patients treated since 2022 remain alive suggesting consistently strong survival benefit. bit.ly/3t51f8J $BCTX $BCTXW
2.3K
BriaCell Therapeutics Corp.
@BriaCell
Nov 10, 2022
BriaCell is pleased to announce positive initial efficacy data in its 2021-2022 cohort of 12 advanced #breastcancer patients. For details: bit.ly/3tp55G5 $BCTX $BCTXW
BriaCell Therapeutics Corp.
@BriaCell
Feb 10, 2022
BriaCell to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update bit.ly/3JlyPcT